Drugs / Recombinant Human Interleukin-21
Recombinant Human Interleukin-21
also known as
rIL-21 · recombinant Interleukin 21 · BMS-982470 · Denenicokin · IL-21 · Interleukin-21
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01629758 | Jun 2012 → Dec 2014 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01489059 | Dec 2011 → Jun 2014 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00347971 | Jun 2006 → Apr 2008 | non-Hodgkin lymphoma | ZymoGenetics | Completed | No outcome recorded |
| Phase 1 | NCT00095108 | May 2004 → Jan 2007 | kidney neoplasm, melanoma, metastatic neoplasm | ZymoGenetics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00389285 | Oct 2006 → May 2009 | renal cell carcinoma | ZymoGenetics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00514085 | Dec 2007 → Sep 2010 | cutaneous melanoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01152788 Comparator | Aug 2010 → Nov 2014 | melanoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human interleukin 21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00347971 ↗ |
| Known as | BMS-982470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489059 ↗ |
| Known as | Denenicokin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01629758 ↗ |
| Known as | IL-21 | “recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties” PMID 24829759 ↗ Jan 2014 |
| Known as | Interleukin-21 | “Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma” NCT01152788 ↗ |
| Known as | recombinant Interleukin 21 | “recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties” PMID 24829759 ↗ Jan 20142“an experimental drug called recombinant interleukin-21 (rIL-21)” NCT00095108 ↗ “BMS-982470 (recombinant interleukin-21)” NCT01489059 ↗ |
| Known as | rIL-21 | “Patients receive recombinant human interleukin-21 (rIL-21) IV on days 1-5 of weeks 1, 3 and 5.” NCT00514085 ↗3“an experimental drug called recombinant interleukin-21 (rIL-21)” NCT00095108 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-21” NCT00095108 ↗ |
| Route | Intravenous | “receive intravenous rIL-21 at least 60 minutes after completing the rituximab infusion at the rest of the weekly dosing visits” NCT00347971 ↗ |